Literature DB >> 8142264

A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer.

S Love1, R J King.   

Abstract

This paper describes a prospective immunohistochemical analysis of 27 kDa heat shock protein (HSP27) in 361 patients with primary breast cancer in relation to disease-free survival (DFS) and survival from first relapse (SR). Oestradiol (ER) and progesterone (PR) receptors were also quantitated and related to the HSP27 data. While ER positively predicted a good outcome for both DFS and SR, HSP27 positivity predicted a prolonged SR but short DFS. The association between HSP27 and DFS only attained statistical significance in node-negative patients. Subgroup analysis reinforced the complementary relationship of HSP27 and ER for SR and opposing influences for DFS. In both node-negative and node-positive women, ER+ HSP27- patients had a longer DFS than ER- HSP27+ counterparts. There was no relationship between HSP27 and overall survival. HSP27 staining was highly correlated with ER but not PR, patient age, tumour size or menstrual status. There was a marginal correlation (P = 0.04) with histological grade with well-differentiated tumours having the highest HSP27. Cox multivariate regression analysis of the contribution of HSP27 in the presence of data on ER, PR, stage, nodal status and histological grade indicated that HSP27 was not of independent prognostic importance for DFS or overall survival and was only of borderline significance for OS (P < 0.07). However, in the absence of ER and PR data, HSP27 staining is an effective way of getting the same prognostic information. HSP27 staining appears to correlate with different biological features in early and advanced breast, high HSP27 being linked with short DFS in node-negative patients but with prolonged survival from first recurrence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142264      PMCID: PMC1968803          DOI: 10.1038/bjc.1994.140

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Immunohistochemical study of cytoplasmic oestradiol receptor in normal, dysplastic and malignant cervical tissue.

Authors:  R J Henry; J D Goodman; M Godley; K S Raju; A I Coffer; R J King
Journal:  Br J Obstet Gynaecol       Date:  1988-09

2.  Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells.

Authors:  D R Ciocca; D J Adams; D P Edwards; R J Bjercke; W L McGuire
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

3.  Monoclonal antibodies against a component related to soluble estrogen receptor.

Authors:  A I Coffer; K M Lewis; A J Brockas; R J King
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

4.  Histochemical studies with an estrogen receptor-related protein in human breast tumors.

Authors:  A Cano; A I Coffer; R Adatia; R R Millis; R D Rubens; R J King
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

5.  Prognostic factors for recurrence and survival in human breast cancer.

Authors:  W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

Review 6.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.

Authors:  A Girling; M Caleffi; R J King; R R Millis
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

8.  Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors.

Authors:  D J Adams; W L McGuire
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Characterization and biological relevance of a 29-kDa, oestrogen receptor-related protein.

Authors:  R J King; J R Finley; A I Coffer; R R Millis; R D Rubens
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  18 in total

1.  Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells.

Authors:  D M Mahvi; S W Carper; C O Yu; T A McCausland; F Kristian Storm
Journal:  Endocrine       Date:  1996-06       Impact factor: 3.633

Review 2.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.

Authors:  Daniel R Ciocca; Stuart K Calderwood
Journal:  Cell Stress Chaperones       Date:  2005       Impact factor: 3.667

3.  Detection and its implication of heat stress protein 27 and P21 in nasopharyngeal carcinoma.

Authors:  L Liu; C Xiao; Y Tao
Journal:  J Tongji Med Univ       Date:  2000

4.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

Review 5.  The role of heat shock proteins in bladder cancer.

Authors:  Joseph Ischia; Alan I So
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 6.  Heat shock proteins in animal neoplasms and human tumours--a comparison.

Authors:  Mariarita Romanucci; Tania Bastow; Leonardo Della Salda
Journal:  Cell Stress Chaperones       Date:  2008-03-12       Impact factor: 3.667

7.  Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer?

Authors:  M Zhao; J X Ding; K Zeng; J Zhao; F Shen; Y X Yin; Q Chen
Journal:  Tumour Biol       Date:  2013-09-06

8.  Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer.

Authors:  Michitaka Kawano; Seiji Kaino; Shogo Amano; Shuhei Shinoda; Shigeyuki Suenaga; Manabu Sen-Yo; Isao Sakaida
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

9.  OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.

Authors:  V Baylot; C Andrieu; M Katsogiannou; D Taieb; S Garcia; S Giusiano; J Acunzo; J Iovanna; M Gleave; C Garrido; P Rocchi
Journal:  Cell Death Dis       Date:  2011-10-20       Impact factor: 8.469

10.  Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas.

Authors:  Olga Kostianets; Stepan Antoniuk; Valeriy Filonenko; Ramziya Kiyamova
Journal:  Diagn Pathol       Date:  2012-11-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.